STERIS (STE) shares have faced pressure recently, with the stock down about 2% over the past month and about 15% over the past 3 months, drawing attention to its current valuation.

Zooming out, the recent 3 month share price decline of about 14.6% and year to date share price decline of about 13.9% contrast with a 5 year total shareholder return of 18.6%. This suggests momentum has softened despite longer term gains.

If you are comparing STERIS with other healthcare related opportunities using technology, this could be a useful moment to scan 35 healthcare AI stocks

With STERIS stock under pressure despite a 5 year total return of 18.6%, are you looking at an undervalued healthcare compounder today, or is the current price already reflecting its future growth?

Most Popular Narrative: 22.9% Undervalued

STERIS's most followed narrative points to a fair value of $279.29 per share compared with the last close at $215.40, putting the current price well below that reference point and centering the discussion on whether the market is discounting its long term earnings power.

Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best practice infection control standards, supporting both revenue and margin expansion.

Want to see what underpins this valuation gap? The narrative describes steady mid single digit revenue growth, thicker margins, and a richer future earnings multiple as key inputs to the valuation framework. The full set of assumptions is where the story really gets interesting.

Result: Fair Value of $279.29 (UNDERVALUED)

However, this upside story could be knocked off course by tariff driven cost pressure on metals and by tighter healthcare reimbursement that squeezes hospital capital budgets.

Another View: Market Multiple Signals Caution

While the popular narrative sees STERIS trading below fair value, the current P/E of 27x is higher than the US Medical Equipment industry at 24.3x, the peer average at 21.4x, and the fair ratio of 23.6x. That premium raises a simple question: how much optimism is already in the price?

Next Steps

If this mix of upside and caution leaves you undecided, review the details promptly and form your own view using the 3 key rewards

Looking for more investment ideas?

If STERIS has caught your attention, do not stop here. Use these focused stock lists to quickly spot other opportunities that could fit your portfolio.

• Target quality at a discount by reviewing the 46 high quality undervalued stocks that combine solid fundamentals with attractive pricing.
• Strengthen your income stream by scanning the 10 dividend fortresses that aim to pair higher yields with resilience.
• Prioritize resilience and sleep easier at night by checking out the 64 resilient stocks with low risk scores built around sturdier balance sheets and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.